MannKind Corporation (Nasdaq: MNKD) today released preliminary top-line results from two pivotal Phase 3 clinical studies of AFRESA(TM), the company's ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE